Top Picks: Accredited Activities

ASH 2018 Annual Meeting Highlights in AML

Naval Daver, MD; Mark J. Levis, MD, PhD; Daniel A. Pollyea, MD; Farhad Ravandi, MD; Eytan M. Stein, MD; and Eunice S. Wang, MD

Evolving Paradigms in AML: Symposium Replay

Farhad Ravandi, MD – Chair; Naval Daver, MD; Guillermo Garcia-Manero, MD; and Richard Stone, MD

  • VIDEO FAQ: Development of a Novel NGS-Based Assay for MRD in FLT3-ITD AML - M. Levis, MD (4:04) - Posted 01/04
    video
  • VIDEO: Managing High-Risk and Relapsed/Refractory AML: Where Is Research Headed Next? - A. Fathi, MD (29:28) - Posted 11/28
    CE video
  • ENEWSLETTER: Optimizing Treatment in the Older Patient with AML - F. Ravandi, MD - Posted 11/06
    text
  • VIDEO FAQ: Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial - E. Stein, MD (4:09) - Posted 01/04
    video
  • FAQ: An overview of the recently approved combination of venetoclax with azacitidine or decitabine or low-dose cytarabine - H. Erba, MD - Posted 12/13
    text
  • Additional activities...

Supporters

MediCom Worldwide, Inc. would like to recognize and thank the following companies for their educational support of Managing AML.com in 2018

  • Agios Pharmaceuticals, Inc.
  • Celgene Corporation
  • Daiichi Sankyo, Inc.
  • Helsinn Healthcare SA
  • Jazz Pharmaceuticals

MediCom Oncology Links

Please visit these other members of the MediCom Oncology family of sites.

Managing MDS Managing Myeloma The Practical Oncologist
Managing Lymphoma Partners in Pancreatic Cancer Emerging Solutions in Pain